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EDITORIAL REVIEW
Biological actions and pathophysiologic significance of
endothelin in the kidney
The control of vascular smooth muscle tone by endothelium-
derived vasoactive autacoids is now well-recognized. Both
vasodilator (prostacyclin, endothelium-derived relaxing factor!
nitric oxide) and vasoconstrictor mediators have been impli-
cated. Among the latter, endothelin (Et), a peptide isolated
from supernatants of cultured porcine aortic endothelial cells
[1], is the first substance to be well-characterized. As a vaso-
constrictor, Et is ten times more potent than angiotensin II,
vasopressin, or neuropeptide Y, making it the most potent
endogenous vasoactive substance known [I]. Importantly, the
biologic actions of Et clearly extend beyond its smooth muscle
constrictor potential to include effects on ion transport, neuro-
transmission, regulation of eicosanoid synthesis, modulation of
renin and atrial natriuretic peptide (ANP) release, and a host of
other actions. The integrated physiologic actions of Et, and its
possible role in pathophysiology, are the subject of intense
international research activities, such that the rate of published
reports on Et biology is exceeding one paper!day since its initial
description in 1988! This review will focus on aspects of Et
biology which have relevance to the kidney, with particular
reference to effects in the normal kidney and kidney cells in
culture, as well as its emerging role in renal pathophysiology.
Peptide structure and gene regulation
Endothelin was first purified from serum-free conditioned
media of cultured porcine aortic endothelial cells by Yanagi-
sawa Ct al [1]. It is a 21 amino acid peptide with two disulfide
bonds bridging amino acids number I to 15 and 3 to 11, the
reduction of which leads to twofold loss of biological activity
(Fig. 1). Two other isopeptides of endothelin have been char-
acterized. The initially isolated human/porcine" endothelin is
now termed endothelin-l (Et-l) and the subsequently identified
endothelins are called Et-2 and Et-3. The genes for all three Et's
are now known to be present in human, pig, and rat genomes,
though the extent and regional specificity of their expression
differ [1—5]. Additionally, the three endothelins are highly
homologous in amino acid sequences and tertiary structure to
certain scorpion and snake venoms, the sarafotoxins.
Endothelin-l is encoded by a single gene in both humans and
pigs [1, 2]. In the human, the Et-l gene appears to be localized
on chromosome 6 [3]. Endothelial cells and cardiac tissue
express exclusively the Et-l gene [4, 5].
The structure of the endothelin gene reveals a number of
important regulatory sites. The first is a pair of octanucleotide
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sequences, "(C!G)TGACT(CIA)A", located at the 5' flanking
region, which represent 'TPA-responsive-elements", and
which imparts a potential role for activated protein kinase C in
the transcriptional regulation of endothelin. The second regu-
latory site is the repetition of an "AUUUA" sequence at the 3'
end. This sequence has been found in mRNA encoding for
several cytokines, growth factors, and proto-oncogenes [6], and
may be involved in the selective destabilization of their
mRNAs. The initial endothelian peptide translation product,
preproendothelin, is 203 amino acids in length [1]. The amino
acid sequence of preproEt-1 contains a single peptide sequence
that is probably cleaved intracellularly to form proEt-1 shortly
after translation (big-Et, Fig. 1). This is accomplished by
dibasic-pair-specific endopeptidases on Lys-Arg and Arg-Arg
pairs which flank the N- and C-terminals of the target sequence
molecule, respectively. The vasoconstrictory actions of proEt-1
are far less potent in vitro than in vivo, implying its further
metabolism under normal physiological conditions [7]. Mature
Et-l is formed by proteolytic cleavage between Trp21-Val22.
This carboxy-terminal cleavage is probably accomplished by an
endopeptidase with chymotrypsin-like activity, which has been
termed endothelin converting enzyme". More detailed re-
views of Et gene structure and regulation have been published
recently [8—10].
Cells of origin
Although endothelin was initially described (and named)
based on its release from large vessel endothelial cells, other
sites of synthesis have been determined subsequently. Endo-
thelin immunoreactivity has been detected in the kidney,
spleen, skeletal muscle, and lung, as well as plasma of the pig
and human [11, 12]. Focusing on the kidney, endothelin release
has been measured in cultured bovine glomerular endothelial
cells [13], isolated rat glomeruli [14], and several cultured renal
cell lines. Uchida et al [15] have shown increased mRNA levels
for endothelin and mature Et-1 release in the cultured renal
tubular epithelial cell lines LLC-PK1 and MDCK. Other inves-
tigators have reported endothelin release from monkey, rabbit,
rat, and hamster cultured kidney cell lines [16] (Table 1). Of
particular interest is the synthesis and release of endothelin
from cultured rat and human mesangial cells [17, 18], in which
exogenous endothelin induces contraction [19].
Endothelin release and endothelin receptors have also been
identified in portions of the brain, spinal cord, posterior pitu-
itary, and dorsal root ganglia in rats and humans [20—23] (Table
I).
Stimuli and release
Thrombin and shear stress induce Et release from endothelial
cells by inducing mRNA transcription [1, 2, 5]. Transforming
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Fig. 1. Pathway of endothelin biosynthesis. The putative secretory
signal sequence and the endothelin sequence are shown by the shaded
and closed boxes, respectively. The rest of the proendothelin sequence
is indicated by an open box. A 39-amino-acid residue intermediate, or
"big endothelin", is considered to be generated from proendothelin by
the proteolytic cleavage at paired basic residues. Mature endothelin is
then produced through an unusual, previously unknown processing by
a putative "endothetin converting enzyme". (Reproduced with permis-
sion from Yanagisawa et al [1]).
growth factor-f31 (TGF-/3l), is also a stimulus for endothelin
release [24]. Endothelin release or expression of preproEt-l
mRNA has also been reported for A23187, ionomycin, arginine-
vasopressin, TPA (protein kinase C activator), epinephrine,
phorbol esters, bradykinin, and interleukin-1 [5, 6, 25—271.
Receptors and signaling
Endothelin acts via specific receptors, through signal trans-
duction pathways which include increases in intracellular free
calcium concentrations and inositol trisphosphate generation
[8—10]. Endothelin-induced contraction of porcine coronary
artery strips is abolished in the absence of extracellular calcium
and attenuated in the presence of a calcium-channel blocker [1].
These observations, coupled with the structural similarities
between Et and a number of membrane-channel-acting peptide
toxins, suggest that Et may induce its biological actions by
facilitating the intracellular influx of Ca2 through voltage-
dependent dihydropyridine-sensitive Ca2 channels [1, 27].
Exposure of cultured rat mesangial cells to 10 nrt Et-1, results
in a rapid intracellular calcium spike tenfold greater than
baseline, followed by a sustained intracellular calcium concen-
tration approximately double the pre-endothelin levels [19, 281.
This is accompanied by a clear dose-dependent increase in
inositol 1 ,4,5-trisphospate (1P3) generation, suggesting release
Mammal
[Reference] Tissue/cell lines
Endothelin
release
mRNA
expression
Dog
[15, 16] MDCK
(Canine kidney, epithelial)
+ +
Hamster
[16] BHK-21
(Golden hamster kidney,
fibroblast)
+ +
Human
[18] Mesangial cells + +
[20—23] Brain/spinal cord + +
Monkey
[16] CV-l
(African green monkey kidney,
fibroblast)
+
Pig
[15] LLC-PKI
(Pig kidney cells)
+ +
[1, 2] Aortic endothelial cells + +
Rabbit
[16] RK-13
(Rabbit kidney, epithelial)
+
Rat
[16] NRK-52E
(Rat kidney, epithelial)
+
[171 Mesangial cells 4 +
of intracellular Ca2 stores. At Et concentrations of 1 n or
less, the calcium response consists of a slow progressive rise
that reaches a plateau within 10 to 20 seconds, is maintained for
20 minutes, and is abolished by removal of extracellular calcium
[19, 28]. Additionally, at Et concentrations of less than I nM, no
significant phosphoinositide turnover is observed [19, 28]. Cu!-
tured rat [29], rabbit [30, 31], bovine, and human [32] smooth
muscle cells all demonstrate calcium spikes and IP generation
in response to endothelin. Taken together, these observations
suggest that, at low concentrations, endothelin may lead to
increases in intracellular calcium through non-phosphoinosi-
tide-mediated mechanisms, such as activation of cell membrane
calcium channels and influx of extracellular calcium [1, 19, 28,
33, 34]; at greater than I flM concentrations, however, Et
provokes intracellular Ca2 release through phospolipase C
activation-dependent mechanisms, and elicits contractile re-
sponses. The dose-related divergence of cellular responses to
Et suggests the presence of more than one class of Et receptors.
Of relevance to the kidney, several investigations have dem-
onstrated the presence of endothelin receptors on mesangial
cells [35—38]. Badr et a] [35] have demonstrated the presence of
two Et-l-specific binding sites on cultured rat mesangial cells
with Kds of 0.76 flM and 44.7 flM, and maximal binding capacity
(Bmax) values of 6.78 x 102 and 27.60 x 102 binding sites/cell,
respectively (Fig. 2). The Kd of 0.76 flM for the high affinity
binding site in the rat mesangial cell agrees with other reports
[36—38]. Additionally, this value is strikingly similar to that
reported for rat renal papillary cell membranes (0.66 nM) [39].
These putative receptors are likely biologically relevant, since
the concentrations at which physiological response to endothe-
un has been observed in these cells are remarkably close to the
dissociation constants [19, 34, 40]. Additional studies, using a
Lys-Arg Arg-Arg
V
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Table 1. Endothelin release and mRNA expression in cultured
mammalian cells
20 53 74 92 203
dibasic
-pair-specific
endopeptidase(s)
Trp-VaI
j C 'big endothelin'
putative 'endothelin-
converting enzyme'
N
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Fig. 2. Scatchard transformation of radioligand binding studies re-
vealing two separate binding sites for endothelin-I on rat mesangial
cells with Kds of 0.76 nM (ER-I) and 44.70 nM (ER-2), and values
of 6.78 x 102 and 27.60 x 102 binding sites/cell, respective/v. (Repro-
duced with permission from Badr et al [35]).
cross-linking technique, have confirmed the presence of two
types of endothelin-specific receptors in cultured rat mesangial
cells [411, which are distinct from voltage dependent L-type
calcium channel. The expression of these receptors may be
regulated by angiotensin II (All) and various phorbol esters in
vascular smooth muscle cells [42], and receptor number may
change in response to ambient Et concentrations (See below).
That multiple forms of the Et receptor exist has been con-
firmed by two recently published reports describing the cloning,
expression and sequence analysis of two separate Et receptors
[43, 44]. Both proteins clearly belong to the family of G-protein
binding membrane receptors, with secondary activation of
inositol phosphate release and increased intracellular calcium
concentrations demonstrated for one of them [44]. One of these
receptors, cloned by Arai et al [431, appears to be highly
selective for Et-l binding when tested in animal cells trans-
fected with the cloned cDNA of the receptor, and is expressed
in central nervous system and widely distributed in peripheral
tissues, particularly lung and heart. The second receptor,
reported by Sakurai et al [44], is non-selective in its binding of
the three Et isotypes, and a messenger RNA corresponding to
its cDNA is detected in rat tissues, including the kidney.
Neither of these two cloned receptor subtypes, however, ap-
pears to be the principal Et receptor on vascular smooth
muscle.
Actions in the normal kidney
A wide array of biological activities and cellular mechanisms
have been described for Et [1, 19, 26, 28—30, 32, 45, 46]. These
include vasoconstriction [1, 19, 26, 47, 48], inotropic [49, 50]
and chronotropic [511 properties, bronchoconstriction [46],
mitogenesis [19, 28], inhibition of renin release [52, 53], and
neurotransmitter function [20—23]. In the kidney, we and others
have reported potent vasoconstrictor and GFR-depressant ac-
tions for this peptide [19, 48, 54, 55]. Endothelin increases renal
vascular resistance and contracts glomerular mesangial cells.
The increase in renal vascular resistance occurs at both afferent
and efferent arteriolar sites; thus, the transcapillary hydraulic
pressure difference is unchanged or somewhat decreased. En-
dothelin-induced mesangial cell contraction is likely the mech-
anism mediating reduction of the glomerular capillary ultrafil-
tration coefficient (Kf) [19, 48]. This latter response is not
evident at low doses [55].
Endothelin contracts rat and rabbit renal afferent and efferent
arterioles in vitro [56, 57]. These studies detected a slightly
greater sensitivity of efferent than afferent arterioles to Et's
contractile actions [561. The differential sensitivity in responses
to exogenous Et between afferent and efferent arterioles may
explain the elevation in intraglomerular capillary pressure dur-
ing exogenous administration observed by King, Brenner and
Anderson [48]. In our studies [19, 55], such increases in P0c
were minimal, likely reflecting small difference in the sensitiv-
ities of efferent versus afferent arterioles to Et (one order of
magnitude in vitro [56]), coupled with the inherent differences
in experimental protocols, inter-laboratory, and interanimal
variability. Nevertheless, these findings suggest distinct differ-
ences in the nature of vascular response to Et at these two
arteriolar sites.
A role for eicosanoids in Et-induced responses has been
suggested. Resink, Scott-Burden and Buhler [32] have demon-
strated direct activation by Et of phospholipase A2 in cultured
vascular smooth muscle cells, raising the possibility of a poten-
tial role for arachidonic acid metabolites in mediating the
cellular actions of endothelin. Thus, endothelin induces release of
prostacyclin and thromboxane A2 (TxA2) from isolated porcine
and rat lungs [261; also indomethacin abolishes endothelin-
induced bronchoconstriction in guinea pigs [46]. In addition,
Zeidel and his colleagues have provided evidence suggesting
the involvement of cyclooxygenase (CO) products in Et-in-
duced inhibition of Na/K-ATPase activity in rabbit inner med-
ullary collecting duct cells [58]. In preliminary in vivo studies,
we evaluated the hemodynamic responses to endothelin in the
rat kidney in the absence and pressure of a cyclooxygenase
enzyme inhibitor (ibuprofen, 20 mg/kg, i.v.) and a specific
thromboxane A2 receptor antagonist [59]. Surprisingly, GFR
was maintained in animals pretreated with ibuprofen, although
the fall in renal plasma flow was similar to non-CO-inhibited
controls. Micropuncture experiments determined that in con-
trast to its constrictor effects on afferent and efferent resis-
tances when infused alone, administration of low dose endo-
thelin in the presence of cyclooxygenase inhibition (but not
thromboxane A2 antagonism) leads to selective increases in
efferent resistance, and hence transcapillary hydraulic pres-
sure, thereby preserving GFR despite falls in renal plasma flow
and Kf. The release of PGF2 from rat glomeruli increased
threefold after addition of l06 M Et, and PGE2 increased
twofold. Since PGF2 is a known renal vasoconstrictor in the
rat kidney, it is possible that the local generation of this
eicosanoid is in part responsible for the endothelin-induced
increase in pre-glomerular resistance observed in vivo. Failure
of CO inhibition to exacerbate the constrictor actions of Et was
also demonstrated in cultured glomerular mesangial cells [40].
Despite compromise of renal blood flow (RBF) and GFR,
infusion of non-pressor doses of Et in the rat is associated with
marked and progressive increases in urinary flow and sodium
excretion [19, 58]. Furthermore, addition of Et to cultured rat
6 U
U
ER-i
2
0
U ER-2
0 1 2 3 4
4 Kon and Badr: Endothelin in the kidney
atrial myocytes stimulates ANP secretion from these cells [45].
We recently investigated whether the secondary release of ANP
was responsible, at least in part, for Et-induced natriuresis [60].
In rats receiving increasing nonpressor doses of Et, plasma
ANP levels showed significant and dramatic increases, despite
absence of changes in systemic arterial pressure. Pretreatment
with a specific rabbit anti-rat ANP antibody markedly blunted
of Et-induced increases in urinary sodium excretion [60]. It thus
appears from these studies, as well as those reported by Fukuda
et al [45] in cultured rat atrial myocytes, that Et is a potent
direct stimulus for the release of ANP, independently of its
effects on mean arterial pressure. The mechanisms by which Et
increases ANP levels in vivo may include direct stimulation of
its cellular release [45], or the induction of an increase in atrial
pressure through its demonstrated potent inotropic actions on
atrial tissue [49, 50]. Thus, Et is affected by and also modulates
actions of other hormones/autacoids.
Pathophysiologic implications of endothelin
Since endothelial cells are important modulators of vascular
dilation and constriction, pathologic processes which affect
endothelial cells may adversely influence vascular function.
Perturbations in elaboration of endothelium-derived substances
do not require morphologically demonstrable endothelial cell
damage. For example, stimulation of EDRF and prostacyclin
(PGI2) production occurs with only minor, or no discernible
changes in the appearance of endothelial cells [61, 62]. Simi-
larly, stimulation of Et production by thrombin, arginine vaso-
pressin, angiotensin II, ionomycin, interleukin 1, endotoxin,
and cyclosporine occurs without visually identifiable cellular
injury [1, 26, 63—65]. Inaddition, cells other than endothelial are
a source for Et; thus, endothelin is also released by perivascular
cells (mesangial cells) as well as non-vascular renal epithelial
cells (LLC-PK1 and MDCK, see above). In this regard, prom-
flammatory agents such as TGF-/3, thromboxane A2 mimetic
and thrombin increase preproEt-l expression and secretion of
Et from cultured human meangial cells [66]. Similarly, TGF-/3,
tumor necrosing factor-a and interleukin-1f3 stimulate Et elab-
oration by renal epithelial cells [67]. Finally, cultured human
macrophages as well as peripheral blood monocytes (but not
lymphocytes or neutrophils) demonstrate positive immunoreac-
tivity for Et, implying that circulating cells may also participate
in activation of or even be the source for endothelin [68]. These
observations indicate that, in a disease state, morphologically
demonstrable endothelial cell damage is not, by any means, a
prerequisite for Et to play an important pathophysiologic role.
Mechanisms of endothelin release in pathophysiologic
conditions
Factors known to precipitate or contribute to renal injury also
can increase Et gene expression and/or its synthesis in vitro,
including hypoxia, anoxia, epinephrine, thrombin, TGF-/3,
shear stress, neuropeptide Y, interleukin-l, endotoxin, and
cyclosporine [1, 26, 63—65, 69—73]. Enhancement in Et produc-
tion in response to these stimuli has also been observed in vivo.
Thus, Et circulates in normal animals and humans [63, 74—76]
and its circulating level has been reported to be increased in
several experimental and clinical settings such as acute renal
failure, chronic renal failure, congestive heart failure, cardio-
genic shock, cyclosporine administration, and endotoxemia [12,
63, 75—85]. Conditions where endogenous Et is elevated parallel
certain phenomena observed when exogenous Et is adminis-
tered, such as systemic hypertension and regional vasoconstric-
tion [63, 77—83, 85]. Besides vasoconstriction, Et induces
mitogenesis of smooth muscle cells, including mesangial cells
with increased matrix production [28, 86, Note added in proof],
stimulates c-myc and c-fos protooncogene expression [871, and
causes cellular hypertrophy 1881. These observations suggest
that Et stimulation may represent an important mechanism for
vascular remodeling and sclerosis.
Although the level of circulating Et can be increased by
injurious stimuli, there is lack of a consistent pattern among and
within disease states. In part, this may reflect differences in the
assay method used [63, 69, 75, 79, 85—90]. However, there may
be biologic factors underlying this variability as well:
1. The extent of injury. Local damage such as renal artery
occlusion may only activate local Et production [91], as com-
pared to systemic insults such as intravenous infusion of
cyclosporine or endotoxin which would induce Et release from
a larger cell population [63, 83].
2. The severity of injury. In patients with essential hyperten-
sion, elevations in plasma Et tend to correlate not with the
degree of hypertension, but with the extent of vascular compli-
cations such as atherosclerosis [77], raising the possibility that
the endothelium from more affected vessels is the principal
source of Et.
3. Heterogeneity in the ability of injured tissue to elaborate
Et. Renal tissue has the highest concentration of Et [92, 93]. It
is possible that damage to the kidney may lead to greater local
release of the peptide, when compared with damage to other
organs such as liver or heart (see below).
4. Capacity to clear or inactivate circulating Et. Although
degradation of circulating Et occurs [94], much of the disap-
pearance of Et from the blood stream rather reflects uptake by
the lungs [94—96]. However, the pulmonary capacity for Et
uptake is saturable. Thus, pretreatment with unlabelled Et
shifts the distribution of subsequently injected labelled Et away
from the lung to the kidney [94]. Similar findings were observed
when endogenous Et was stimulated by infusion of endotoxin
[79]. Of interest, clearance of elevated Et in this instance was
not accomplished by the lung, but instead by kidney, spleen and
hindlimb [11]. These observations suggest that elevation in
circulating Et may reflect not only increased production but
also impairment in clearance. For example, pulmonary impair-
ment in congestive heart failure may preclude efficient Et
clearance [84]. Similarly, bilateral nephrectomy causes a mod-
est but significant delay in the disappearance of exogenous Et,
in association with a more pronounced hypertensive effect [97].
Elevated levels of circulating Et in patients on hemodialysis [75,
76] may, at least in part, relate to the absence of functioning
renal parenchyma.
5. Local concentration at the vascular smooth muscle. Re-
lease of Et may be primarily targeting the effector loci, namely
the vascular smooth muscle cell. Even if Et release were
bidirectional, that is, luminal and antiluminal, the concentration
of Et in the local tissue fluid may greatly exceed that in the
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blood [96]. Of interest, Morel et a! [80] found that continuous
administration of endotoxin increased endogenously produced
endothelin both in plasma and thoracic lymph, whereas infusion
of exogenous endothelin caused an increase in Et level only in
the plasma and not in the lymph. The implication of these
observations is that exogenous Et does not enter the extravas-
cular space, and, in view of the rapid disappearance of Et from
the circulation, the observed elevation in the lymphatic Et may
reflect antiluminal release of endogenous EL
6. Finally, although endogenous Et in the circulation can be
increased by injurious stimuli, the elevation is short-lasting.
Both exogenously administrated and endogenously produced
Et promptly disappear from the circulation [94—96, 98]. More
than 50% of exogenous Et injected into guinea pigs is cleared by
the lungs in a single passage, predicting that circulating Et
would disappear completely in one to two minutes [95, 96].
Importantly, despite the fall in circulating Et, glomerular dys-
function persists and can be ameliorated by antagonizing the
local endothelin by endothelin antiserum (see below). This
dissociation between elimination of endothelin and the time
course for its vascular effects was noted initially by Yanagisawa
et a!: in vivo, a single injection of Et caused sustained hyper-
tension lasting almost an hour; in vitro, endothelin-induced
constriction of vascular strips was unresponsive to washing [1].
Overall, it appears that the current data supports the view that
a persistent elevation in circulating Et is not required for its
potent constrictor actions in specific vascular beds.
Regional heterogeneity of the effects of endothelin
Renal susceptibility
Endothelin affects all vessels, although its actions on different
vascular beds are not uniform. The renal circulation is particu-
larly susceptible to the vasoconstricting effects of exogenous Et
[99, 100] (Fig. 3). Ultrasonic flow-probe assessment of regional
blood flow in the pig reveals that the renal vasculature is tenfold
more sensitive to Et than the bronchial, femoral, and coronary
vessels (Fig. 3) [99]. Similar results were obtained in the
squirrel monkey [100] where a dose of Et (3 mg/kg) which
reduced the coronary blood flow by 46% caused virtual cessa-
tion of blood flow in the kidney [100].
The reasons for the renal susceptibility to Et have not been
well delineated but may be related to differences in the capa-
bility to produce and/or bind Et. The highest concentration of
Et among various tissues of normal rats and pigs are found in
the kidneys [92, 93], possibly relating to the observation that in
addition to endothelial cells, the glomerular mesangial cells as
well as renal epithelial cells can synthesize Et [15]. Et is
excreted into the urine and in patients with renal disease, its
clearance exceeds that of creatinine, suggesting tubule secre-
tion [101]. These findings are of interest since Et exerts inhib-
itory effects on Na-K ATPase activity and vasopressin-
induced cyclic AMP accumulation [58, 102] and may, therefore,
play a role in the altered tubule reabsorptive capacity of
chronically damaged kidneys. It is also possible that high renal
concentration of Et (with powerful influence on cellular prolif-
eration and hypertrophy) contributes to the vascular remodel-
ing which occurs during progression of renal damage. With
regard to Et receptors, the rat kidney has a very high density of
Et binding sites in glomeruli and inner medulla. Among conduit
200 400
Endothelin, pmo/kg
Fig. 3. Effect of exogenous endothelin on various circulatory beds in
the pig: renal (closed circles); coronary (open circles);femoral (closed
triangles); bronchial (open triangles). (Reprinted with permission from
Pernow J, et al [99]).
vessels, the renal artery has the highest density of Et receptors
[103]. As will be discussed below, renal receptors for Et may be
specifically affected by injury.
Specific pathophysiologic conditions
Postischemic renal failure
It has long been recognized that hypoxia/anoxia potentiate
vascular contraction in response to certain constrictors such as
norepinephrine [104], and that the hypoxic/anoxic potentiation
is reduced with endothelia! denudation [105, 106]. Although
tissue hypoxia is one of a multitude of seque!ae in ischemia, it
is likely that, at least in part, this endothelium-dependent
facilitation of vasoconstriction observed with hypoxia/anoxia
was due to Et. This has been demonstrated in cardiac and renal
tissue. Increased levels of circulating Et have been noted in
association with tissue hypoxia occurring during experimental
myocardial infarction in rats, as well as in humans during the
first hours of acute ischemia in myocardia! infarction [78, 81]. In
the animal study (one hour of coronary artery ligation followed
by 24 hours of reperfusion), plasma Et increased from 0.93 to
4.0 pg/mI, while cardiac tissue level increased from 5.0 to 33.1
pg/g of tissue [81]. In the renal parenchyma, the Et concentra-
tion increases over 24 hours following an initial 45 minutes of
bilateral renal artery occlusion [91]. Of interest, the circulating
level of Et in these experimental animals was not different from
normal controls. Treatment with a monoclonal antibody to Et (5
minutes before and 5, 60 and 120 minutes after release of renal
occlusion) lessened accumulation of BUN and creatinine, pro-
tected from development of renal edema and histological dam-
age, and suppressed accumulation of calcium in necrotic tissue
[91].
The possibility that the vasoconstriction which characteristi-
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Fig. 4. Schematic illustration of infusing a branch of the main renal
artery. This permits specific treatments of different populations of
glomeruli in a kidney which has previously sustained a generalized
injury of all the glomeruli. Glomeruli I reflect nephron function follow-
ing the generalized injury (such as renal artery occlusion or intravenous
infusion of cyclosporine); while Glomeruli 2 represent function in
nephrons having sustained the same initial damage which were subse-
quently also xposed to anti-endothelin serum. (Reprinted with permis-
sion from Kon V, et al [55]).
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cally follows renal ischemia depends upon endogenous Et has
been assessed in functional studies. Forty-eight hours after 25
minutes of renal artery clamping, kidneys were micropunctured
while anti-endothelin serum was being infused into one of the
branches of the main renal artery (Fig. 4) [55]. When compared
with glomeruli not exposed to the antiserum, infused glomeruli
showed a remarkable amelioration in the vasoconstriction, with
an almost 60% increase in the SNGFR and doubling in the
glomerular plasma flow rate. Compared with non-infused gb-
meruli, there was also an increase in the gbomerular capillary
pressure and fall in both afferent and efferent arteriolar resis-
tances. The exact mechanism for the beneficial effect of Et
antibody remains to be elucidated, however, it likely involves
antiserum-associated changes in post-receptor events (rather
than binding to circulating Et).
Of note, tissue ischemia also appears to potentiate Et's
vasoconstricting and toxic effects. A doubling of the vasocon-
strictor potency of exogenous Et and an increase in its myocar-
dial toxicity were observed in rats made hypoxemic by lowering
their ventilation volume [107]. It was postulated that this
enhanced effect may be related to changes in the characteristics
of Et receptors, or efficiency of coupling to effector mecha-
nisms. In this regard, ischemia has been shown to increase
density of Et-l binding sites in rat cardiac membranes [108,
109]. In particular, the increased binding following ischemia
was observed in the crude plasma membrane fraction while the
light membrane fraction binding, presumably representing the
intracellular component, fell [108, 109]. The results were taken
to show that ischemia externalizes cardiac binding sites for Et.
It should be noted that hypoperfusion, and therefore, the
potential for tissue hypoxia, is a regular feature of injuries
which lead to renal dysfunction. Thus, any disorder with
hypoperfusion as a feature may activate and/or potentiate a
pathophysiologic role for Et.
Endotoxemia
Endotoxemia is associated with a variety of cardiovascular
effects including systemic hypotension/hypertension, and vaso-
constriction of various vascular beds, notably pulmonary and
renal [110—112]. Intravenous injection of the endotoxin into rats
was associated with a prompt (occurring in 10 to 15 minutes)
increase in circulating Et to —120 pg/mI compared with < 2
pg/mI in control rats [63]. This in vivo activation of Et by
endotoxin has been confirmed in other studies [79, 80]. Figure 5
shows that while systemic injection of endotoxin caused a
profound decrease in GFR, Et antiserum infused into the left
main renal artery ameliorated renal hypofiltration on that side
but not in the contralateral non-infused kidney (unpublished
observations). In companion studies, in cultured bovine trans-
formed thoracic aorta endothelial cells, addition of E. coli
endotoxin to the culture medium increased the release of Et in
a dose dependent manner [63].
Cyclosporine toxicity
Cyclosporin A is an immunosuppressant which has dramati-
cally improved graft survival of different organ transplants in
the last decade. Among its recognized adverse side effects,
which include hepatotoxicity, hypertension, and central ner-
vous system toxicity, nephrotoxicity is most prominent [113,
114]. Cyclosporine nephrotoxicity encompasses a spectrum of
clinical presentations from precipitous decrease in GFR to
chronically progressive scarring. It is estimated that GFR
decreases by at least 20% in almost all patients treated with the
drug [114], however, the decline which occurs in the first two to
six months of therapy can be reversed by reducing/withholding
cyclosporine [113, 114]. This early renal involvement appears to
reflect intense, reversible renal vasoconstriction and has been
linked to the renin-angiotensin and adrenergic systems, and
thromboxane A2 [115—117]. It is likely that renal vasospasm, at
least in part, may also reflect altered vascular reactivity due to
endothelial cell damage.
There is both functional and morphological evidence for
disruption of endothelial cell integrity by cyclosporine [118-.
122]. A recent report underscores cycbosporine microangio-
pathic injury [123]. Shortly after a renal transplant, a patient
received two doses of rapid intravascular infusion of cyclospo-
rine, which was associated with an abrupt decrease in urine
output. Subsequently, renal biopsy (and later nephrectomy)
revealed an unusual and severe vascular injury in the graft (Fig.
6). Histological examination showed extensive vascular injury
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Fig. 5. Glomerular filtration rate (GFR) in the right (R) and left (L)
kidneys during baseline (open bars), systemic administration of endo-
toxin (black bars) and during infusion of anti-endothelin serum through
the main renal artery into the left kidney (stippled bars).
Fig. 6. Transplanted kidney in a patient who received rapid mt rave-
nous infusion of cyclosporine. (A) Extensive necrosis with interlobular
artery filled with nuclear debris. No viable endothelial cells remained in
medium-sized arteries, arterioles or capillaries (periodic acid Schiff, x
700). (B)Close-up of a segmental artery showing absence of endothelial
cells, with polymorphonuclear cells adherent to the denuded vessel
wall, Immunofluorescence showed no immunoglobulins or complement
and no leukocytes were found in the vessel wall (periodic acid Schiff, x
500). (Fogo, A et al [123]. Color figure is produced for this publication
through the support of Sandoz Pharmaceuticals).
and necrosis with sloughing of the endothelial cells in all the
renal vessels, including glomeruli, arterioles and large arteries.
The circulating level of Et shortly after cyclosporine infusions
was more than double this patient's pre-transpiant value (or
values typically seen in patients on hemodialysis), and de-
creased after cessation of cyclosporine and removal of the graft.
These observations support the notion that endothelial cells
may be a target for cyclosporine toxicity and that the patho-
physiology of cyclosporine-induced glomerular dysfunction in-
volves Et release from injured cells. The latter may include
endothelial, mesangial and epithelial cells of the kidney, as well
as susceptible cells in the systemic circulation.
This dramatic case exemplifies the extreme in the spectrum of
cyclosporine treatment. However, as discussed above, changes
in endothelial elaboration of vasoactive substances may pro-
ceed without morphologically demonstrable abnormalities, and
may occur in cyclosporine induced glomerular dysfunction not
C
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accompanied by vascular injury. In vivo experiments showed
that intravenous administration of cyclosporine in rats (20
mg/kg) which caused no vascular damage as assessed by light
and electron microscopy, increased the endogenous circulating
Et level (43 pg/mI, vs. < 2 pg/mI controls) [83]. Of note, the
elevation in Et level occurred in association with an increase in
the systemic blood pressure (by some 20 mm Hg at the time of
blood collection), an observation in agreement with the well-
recognized hypertensive effect of exogenous Et.
The study also examined the functional consequences of
cyclosporine treatment on glomerular hemodynamics [83]. One
hour following cyclosporine administration, rabbit anti-porcine
Et serum was infused continuously into a first order branch of
the main renal artery. The glomeruli not infused with Et
antiserum as well as those infused with Et antiserum were
simultaneously assessed by micropuncture (Fig. 4). A dramat-
ically different hemodynamic pattern was seen in the two
groups of nephrons of the same kidney (Fig. 7). Compared with
the more than 40% fall in SNGFR observed after cyclosporine
administration, SNGFR in glomeruli within the same injured
kidneys which were also exposed to Et antiserum was only 20%
lower than the baseline value. Amelioration in hypoperfusion,
in association with lower afferent and efferent arteriolar resis-
tances, was also apparent in the cyclosporine-injured glomeruli
infused with Et antiserum. Perico et al also found that Et
antiserum ameliorated renal hypoperfusion and hypofiltration
following intravenous administration of cyclosporine in rats
[124]. These workers also showed that Et antiserum treatment
of isolated perfused kidneys, which are devoid of systemic
input from the sympathetic and renin-angiotensin systems,
successfully ameliorated cyclosporine-induced renal dysfunc-
tion. Moreover, although Et antiserum prevented deterioration
in renal function in response to bolus injection of Et (150 pmol),
it was ineffective in preventing renal vasoconstriction following
infusions of substances previously implicated in cyclosporine
—
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Fig. 7. Change from baseline values in the microcircu/atory parame-
ters in cyclosporine treated kidneys comparing glomeruli which were
not exposed (black bars; Glomeruli I in Fig. 5) with those which were
exposed to anti-endot he/in serum (stippled bars: Glomeruli I in Fig. 5).
(Reprinted with permission from Kon V. et al [83]).
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nephrotoxicity, including angiotensin II, norepinephrine or a
thromboxane A2 mimetic.
It is clear that injurious stimuli, including cyclosporine, can
promptly stimulate endogenous Et production. However, as
noted earlier, persistent elevation in circulating endothelin level
is not necessary to effect its compelling actions. Thus, in our
study, by 60 minutes after cyclosporine, at a time when
glomerular hypoperfusion and hypofiltration prevail, the circu-
lating level of Et is close to that found in normal rats [1251 and
implies persistent activation of vascular smooth muscles occurs
at the receptor or post-receptor level. In recent studies, Awazu
et al found increased Et binding in glomeruli of cyclosporine
treated animals [125]. This increased binding appears specific
for Et since cyclosporine treatment did not alter the receptor
binding characteristics of angiotensin II. It also appears kidney-
specific since there was no difference in Et binding in hepatic
tissue between cyclosporine and control rats. In similar studies,
Nambi et al also showed that cyclosporine treatment (50 mg/kg
intraperitoneally) for four days resulted in decreased GFR in
association with a 60% increase in Et receptor density in renal
tissue [1261. The pathophysiologic implications of Et are still
not completely understood, however, it appears that cyclospo-
rine-induced glomerular dysfunction involves upregulation of
glomerular Et receptors and that this alteration in Et receptors
is specific to the kidney.
Hypertension
Increased vascular resistance in systemic and regional ves-
sels observed in hypertensive states has been linked to en-
hanced vascular reactivity. This observation raises the possi-
bility that hypertensive endothelial damage increases Et
activity, which in turn participates in the abnormal regulation of
blood pressure. In addition, Et directly potentiates the release
of other regulators of vasomotor tone including norepinephrine
and aldosterone, which themselves may contribute to the
development of hypertension [71, 1271. Finally, as noted above,
Et's ability to influence cellular proliferation and hypertrophy
may be a factor in vascular remodeling occurring in hyperten-
sion.
A recent case describes two patients with malignant heman-
gioendothelioma, a rare vascular neoplasm which is character-
ized by proliferation of endothelium, who presented with sys-
temic hypertension and elevated circulating levels of Et [128].
The tumor contained eight times more Et per gram wet tissue
weight and three times more Et mRNA expression than normal
skin. In both patients, surgical removal of the tumor was
associated with decreased systemic blood pressure together
with a fall in the circulating Et into the normal range. Recur-
rence of the tumor in one of the patients was accompanied by
higher plasma Et levels together with higher systemic blood
pressure. Although this report is intriguing, systemic hyperten-
sion is not clearly related to elevations in circulating levels of
Et. Thus, while one study found that the plasma Et in patients
with essential hypertension was elevated [77], other studies
found no differences between untreated hypertensive and age-
matched controls [129]. In one human study, a negative corre-
lation was found between Et and systolic blood pressure in
hypertensive subjects, while a positive correlation was noted in
normals [129]. In animal studies, plasma Et level in doxycorti-
costerone acetate (DOCA)-salt rats were not different from
sham-operated controls [1301. Furthermore, plasma levels of Et
and its precursor were significantly lower in 15-week-old spon-
taneously hypertensive rats (SHR) and stroke-prone SHR
(SHR-SP) than in normal Wistar-Kyoto rats, suggesting that
increased circulating Et is not necessary for the maintenance of
hypertension. Of interest, similar to the human [129], the
plasma concentration of Et and big Et were significantly lower
in the more hypertensive SHR-SP than SHR rats, implying that
production of Et is decreased with more severe hypertension
[130]. The findings by Kitamura et al that the concentration of
immunoreactive Et in the renal inner medulla is significantly
lower in SHR than in control WKY further support this
possibility [131].
The vascular responsiveness to Et in large capacitance ves-
sels (aorta and renal and mesenteric arteries) of genetically
hypertensive rats is increased [132—134]. Similarly, microves-
sels in the mesenteric circulation of DOCA-salt and Goldblatt II
hypertensive rats studied in vivo show enhanced vascular
reactivity to Et [134]. However, this hyperactivity of vessels
from hypertensive animals may not be unique to Et [135, 136].
In addition, other in vivo studies found only modest [137] or
even absent [138] heightened sensitivity to exogenous Et com-
pared with in vitro studies. The more modest in vivo effects of
Et have been ascribed to activation of compensatory mecha-
nisms in intact animals, involving vasodilating prostaglandins,
EDRF and atrial natriuretic factors as well as differences in the
baseline blood pressure between hypertensive and control
animals. Altered receptor binding of Et to vascular smooth
muscle cells has been postulated as a possible mechanism for
increased vascular reactivity to Et. However, Clozel showed
that the binding affinity of '251-Et is similar in smooth muscle
cell cultures originating from SHR versus Wistar Kyoto rats.
Furthermore, the density of the Et binding sites is significantly
lower in the SHR [132]. It appears, therefore, that if Et plays a
role in the maintenance of hypertension, its effect may reside in
postreceptor events, such as enhanced phosphotidylinositol
generation or activation of protein kinase C [139].
In summary, endothelial cell injury can induce endothelin
release; however, discernible morphologic disruption is not a
prerequisite. In fact, endothelial cells themselves may not be
required for endothelin release, since other cell types can
elaborate endothelin. While injurious stimuli can activate
endogenous endothelin and elevate circulating levels, continu-
ous elevation in circulating endothelin may not be necessary for
its profound effects. Instead, local endothelin activity which
encompasses local concentration of endothelin or its receptor
as well as post-receptor mechanisms, may be of major impor-
tance. These local factors may be enhanced in the renal
circulation, underlying renal susceptibility to injuries which
involve activation of endothelin.
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